Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 9/20 | 0.60 |
| ▸ | UTS2R | Q9UKP6 | 8/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.60 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2957820 | 0.93 | UTS2R (0.52) | OPRK1UTS2RCYP3A4CYP2D6ROCK2 | |
| SCHEMBL3117129 | 0.93 | OPRK1 (0.56) | OPRK1UTS2RCYP3A4CYP2D6OPRD1 | |
| SCHEMBL2954070 | 0.91 | OPRK1 (0.73) | OPRK1UTS2RCYP3A4CYP2D6DPP4 | |
| SCHEMBL3109022 | 0.87 | OPRK1 (0.51) | OPRK1UTS2RCYP3A4CYP2D6 | |
| SCHEMBL3109146 | 0.86 | OPRK1 (0.45) | OPRK1UTS2RCYP3A4CYP2D6RPS6KB1 | |
| SCHEMBL3106333 | 0.85 | OPRK1 (0.64) | OPRK1UTS2RCYP3A4CYP2D6DPP4 | |
| SCHEMBL3111936 | 0.84 | UTS2R (0.55) | OPRK1UTS2RCYP3A4CYP2D6 | |
| SCHEMBL2956624 | 0.84 | UTS2R (0.58) | OPRK1UTS2RCYP3A4CYP2D6 | |
| SCHEMBL2957692 | 0.83 | OPRK1 (0.83) | OPRK1UTS2RCYP3A4CYP2D6OPRD1 | |
| SCHEMBL2955694 | 0.83 | OPRK1 (0.83) | OPRK1UTS2RCYP3A4CYP2D6OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256130-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | GOODMAN KRISTA B | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256130-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | UTS2R, AVPR2, VIPR2 | OPRK1 207/4885UTS2R 1/4885CYP3A4 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.